Understanding the Connection between Muscle Protein Synthesis and GLP-1 Agonists
Glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1RAs) have revolutionized the management of obesity and type 2 diabetes, demonstrating significant efficacy in inducing weight loss and improving metabolic parameters. However, emerging clinical and paraclinical evidence suggests that these agents may also contribute to an unintended reduction in skeletal muscle mass, potentially exacerbating or precipitating sarcopenia.
The Mechanisms of Action of GLP-1 Agonists
GLP-1RAs work by mimicking the natural GLP-1 hormone, which is released by the gut in response to eating and has several effects that help regulate blood sugar levels, hunger, and slow digestion. These medications trigger such effective appetite suppression that patients inadvertently enter a state where their bodies break down muscle tissue for energy, leading to muscle loss.
The Importance of Muscle Protein Synthesis
- Glucose and protein metabolism play critical roles in skeletal muscle function and mass.
- GLP-1 and GLP-1RAs recruit microvasculature in muscle, influencing glucose and protein metabolism.
- Studies have shown that GLP-1RAs can mildly reduce absolute muscle mass but improve relative mass and running performance in mice.
Protecting Lean Mass during GLP-1 Treatment
Resistance training twice weekly can reduce GLP-1-induced muscle loss by up to 60%. Consuming 1.2-1.6g protein per kg body weight daily helps maintain lean mass during treatment. GLP-1 receptor agonists like Ozempic and Wegovy require high protein intake (0.8-1g/lb), resistance training, and nutritional monitoring to prevent muscle loss.
